Onxeo Archives

News and Trends 27 Jan 2023

Onxeo to study prostate cancer drug

French biotech company Onxeo S.A. has given an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first U.S. clinical study site, Next Oncology San Antonio. This phase 1b/2 multicenter, basket trial intends to assess the safety and preliminary activity of AsiDNA in combination with olaparib in patients […]

January 27, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 2 Sep 2022

Cancer drug for children and young people with glioblastoma given to patients in study

Clinical-stage bio company, Onxeo, has announced that the first patients have been enrolled and treated in a phase 1b/2 clinical study. The study is to evaluate the efficacy and tolerability of AsiDNA2, a DDR inhibitor combined with radiotherapy in children, adolescents or young adults with relapsed high grade glioma (HGG). Onxeo, which focuses on drugs […]

September 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Nov 2018

DNA Repair Treatment Shows Early Promise for Treating Cancer

Paris-based Onxeo has proved in humans the potential of a cancer treatment that interferes with DNA repair mechanisms. The therapy has potential to work in a wide range of tumors without cancer cells becoming resistant. Onxeo has reported preliminary results from an ongoing Phase I trial in which six different doses will be tested. […]

November 5, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Apr 2018

Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time

Onxeo has initiated a Phase I trial testing its first-in-class cancer treatment that works by inhibiting the repair of tumor DNA. Onxeo, a French biotech, has dosed its first patient in a Phase I study testing its cancer treatment AsiDNA, the first treatment of its kind, for advanced solid tumors. The news follows the Phase […]

April 25, 2018 - 1 minutemin - By Alexander Burik

News and Trends 12 Sep 2017

French Nanoparticle Therapy Fails to Improve Liver Cancer Treatment in Phase III

Onxeo has announced Phase III results for its nanoparticle chemotherapy Livatag, which failed to improve the outcome for patients with hepatocellular carcinoma compared to other available treatments. The stock of the French oncology specialist Onxeo was halved this morning when it revealed the results of a Phase III trial with its candidate Livatag that failed to […]

September 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

blood cancer disease model, multi-omics, CAR-T, oncology

News and Trends 28 May 2016

It’s Blood Cancer Day, how is Biotech fixing it?

Today is the World Blood Cancer Day, an event to show solidarity to patients and raise awareness for the need of better therapies to treat these cancers – which are still often deadly. Blood cancers can affect different type of cells in the blood. Because these cells are so close to the circulatory and immune system, […]

May 28, 2016 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 11 Nov 2015

French-Danish Clinical Trial Made Blood Cancer Disappear in 72% of Patients

Onxeo is the French orphan-drug specialist in Oncology who has various pipelines for certain cancers. Now their phase I clinical trial of belinostat (trade name Beleodaq) combined with chemo for relapses in non-Hodgkin Lymphomas has shown an 89% response rate. Originally developed by TopoTarget (a biotech in Copenhagen) Belinostat is now under Onxeo’s portfolio (along […]

November 11, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 25 Sep 2015

Two French Biotechs are fighting in court…for nothing

We are all familiar with stories of lawsuits in the tech sector (e.g. remember the Apple and Samsung debacle?) but it’s less well known for Biotechs to butt heads. Nonetheless, the French-Danish Biotech oncology company Onxeo, and Eurofins (a huge 19K employee group which deals in clinical services) fought it out in Paris’ commerce court: to […]

September 25, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 14 Nov 2014

Onxeo confirms receipt of the $25M milestone payment from its US partner Spectrum

Onxeo, an innovative company specializing in the development of orphan oncology drugs, founded after the merger of BioAlliance Pharma and Topotarget, announces that it has received from his US partner Spectrum Pharmaceuticals the milestone payment of $25 million related to the approval of Beleodaq by the FDA. Early July 2014, Beleodaq was granted by the […]

November 14, 2014 - 3 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us